Mao Yayun, Huang Meiping, Liu Jiafu
Fuzhou Pulmonary Hospital of Fujian, Clinical Teaching Hospital of Fujian Medical University, Fuzhou, Fujian, 350008, China.
Lung Cancer Manag. 2024 May 15;13(1):LMT64. doi: 10.2217/lmt-2023-0012. eCollection 2024.
Managing extensive-stage SCLC (ES-SCLC) has long been challenging for clinicians and oncologists due to its aggressive nature and poor prognosis. We report a case of a 41-year-old female with ES-SCLC who survived for six years, defying the disease's typically poor prognosis. Through a heavy treatment strategy involving chemotherapy, targeted therapy, and immunotherapy, the patient experienced robust responses and avoided distant metastasis, including brain involvement. The long-term survival case in SCLC highlights the need for further research into personalized strategies and prognostic biomarkers. This case holds significant value for both clinicians and researchers as it challenges the conventional strategies for ES-SCLC and sets the stage for future evidence-based studies aimed at extending survival in SCLC.
由于广泛期小细胞肺癌(ES-SCLC)具有侵袭性且预后较差,长期以来,临床医生和肿瘤学家对其治疗一直颇具挑战。我们报告了一例41岁的ES-SCLC女性患者,她存活了六年,打破了该疾病通常较差的预后。通过包括化疗、靶向治疗和免疫治疗在内的强化治疗策略,该患者获得了显著疗效,避免了远处转移,包括脑转移。小细胞肺癌的这一长期生存病例凸显了对个性化策略和预后生物标志物进行进一步研究的必要性。该病例对临床医生和研究人员均具有重要价值,因为它挑战了ES-SCLC的传统治疗策略,并为未来旨在延长小细胞肺癌患者生存期的循证研究奠定了基础。